Edesa Biotech Statistics
Total Valuation
Edesa Biotech has a market cap or net worth of $48.52 million. The enterprise value is $38.51 million.
| Market Cap | 48.52M |
| Enterprise Value | 38.51M |
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Edesa Biotech has 8.89 million shares outstanding. The number of shares has increased by 102.57% in one year.
| Current Share Class | 8.89M |
| Shares Outstanding | 8.89M |
| Shares Change (YoY) | +102.57% |
| Shares Change (QoQ) | +7.98% |
| Owned by Insiders (%) | 13.35% |
| Owned by Institutions (%) | 19.88% |
| Float | 5.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 26.63 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.76
| Current Ratio | 4.76 |
| Quick Ratio | 4.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -81.16% and return on invested capital (ROIC) is -53.49%.
| Return on Equity (ROE) | -81.16% |
| Return on Assets (ROA) | -47.73% |
| Return on Invested Capital (ROIC) | -53.49% |
| Return on Capital Employed (ROCE) | -108.00% |
| Weighted Average Cost of Capital (WACC) | 10.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$614,343 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Edesa Biotech has paid $800 in taxes.
| Income Tax | 800 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +180.00% in the last 52 weeks. The beta is 1.07, so Edesa Biotech's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +180.00% |
| 50-Day Moving Average | 9.48 |
| 200-Day Moving Average | 4.15 |
| Relative Strength Index (RSI) | 34.29 |
| Average Volume (20 Days) | 349,007 |
Short Selling Information
The latest short interest is 218,598, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 218,598 |
| Short Previous Month | 513,538 |
| Short % of Shares Out | 2.46% |
| Short % of Float | 3.95% |
| Short Ratio (days to cover) | 0.56 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.01M |
| Pretax Income | -10.44M |
| Net Income | -10.44M |
| EBITDA | -10.91M |
| EBIT | -11.01M |
| Earnings Per Share (EPS) | -$1.37 |
Balance Sheet
The company has $10.00 million in cash and n/a in debt, with a net cash position of $10.00 million or $1.13 per share.
| Cash & Cash Equivalents | 10.00M |
| Total Debt | n/a |
| Net Cash | 10.00M |
| Net Cash Per Share | $1.13 |
| Equity (Book Value) | 10.20M |
| Book Value Per Share | 0.21 |
| Working Capital | 8.23M |
Cash Flow
| Operating Cash Flow | -7.53M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 102,987 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.53M |
| FCF Per Share | -$0.85 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Edesa Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.57% |
| Shareholder Yield | -102.57% |
| Earnings Yield | -21.53% |
| FCF Yield | -15.51% |
Analyst Forecast
The average price target for Edesa Biotech is $14.00, which is 156.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.00 |
| Price Target Difference | 156.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 11, 2023. It was a reverse split with a ratio of 1:7.
| Last Split Date | Oct 11, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |